Neuroone Medical Technologies (NMTC) Cash & Equivalents (2017 - 2026)

Neuroone Medical Technologies (NMTC) has reported Cash & Equivalents for 10 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 74.53% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (down 74.53% YoY), and the FY2025 full-year result was $6.6 million, up 350.01% from the prior year.
• Cash & Equivalents eased to $2.0 million in Q2 2026 per NMTC's latest filing, from $2.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $12.9 million in Q1 2022 and bottomed at $1.1 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $4.5 million across 5 years, with a median of $3.3 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents jumped 396.28% in 2025, then tumbled 74.53% in 2026.
• Over 5 years, Cash & Equivalents stood at $4.7 million in 2022, then sank by 42.56% to $2.7 million in 2023, then plunged by 57.69% to $1.1 million in 2024, then surged by 217.36% to $3.6 million in 2025, then slumped by 43.12% to $2.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.0 million, $2.8 million, and $3.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.